TScan Therapeutics (TCRX) Price to Book (2021 - 2026)

TScan Therapeutics (TCRX) has reported Price to Book for 6 consecutive years, with 1.85 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to Book rose 73.34% year-over-year to 1.85 in Q2 2026; TTM through Jun 2026 was 1.85, a 73.34% increase from a year earlier, with the FY2025 full-year figure at 1.05, down 25.39% from the prior year.
• Price to Book was 1.85 for Q2 2026 at TScan Therapeutics, up from 1.35 in the prior quarter.
• Over five years, Price to Book peaked at 6.13 in Q1 2024 and troughed at 0.37 in Q4 2022.
• A 5-year average of 1.55 and a median of 1.21 in 2026 frame the typical range for Price to Book.
• Across the five-year window, Price to Book surged 839.47% in 2024 and slumped 86.1% in 2025, its largest moves.
• Over 5 years, Price to Book stood at 0.37 in 2022, then soared by 576.23% to 2.53 in 2023, then sank by 44.27% to 1.41 in 2024, then dropped by 25.39% to 1.05 in 2025, then jumped by 75.05% to 1.85 in 2026.
• The last three Price to Book figures came in at 1.85 (Q2 2026), 1.35 (Q1 2026), and 1.05 (Q4 2025), per Business Quant data.